Sedana Medical to host conference call to provide first quarter 2018 business update
On May 22, 2018, at 12:30 pm CET, Sedana Medical AB (publ) (Sedana Medical or the Company) will publish its interim report for the first quarter 2018. All interested parties are invited to participate in a web-cast telephone conference, which will include a presentation, on the same day at 2.30 pm CET. The event will be hosted by Sedana Medical's CEO Christer Ahlberg and CMO Peter Sackey. The presentation will be held in English.
How to participate:
The live webcast and a recorded on-demand version including the presentation material will be accessible at:
Questions can be asked in writing via the webcast or verbally via the conference call.
To participate in the conference call, please call one of the following numbers:
• SE: +46856642662
• DE: +4969222229046
• FI: +358981710493
• FR: +33170750712
• UK: +442030089802
• NL: +31207168416
• US: +18557532235
The presentation material will also be published on Sedana Medical's website www.sedanamedical.com under Investors/ Presentations. The webcast, and later the recorded version of the webcast and the conference call, will also be accessible via Sedana Medical’s website.
For additional information, please contact:
Christer Ahlberg, CEO, Sedana Medical AB
+46 70 675 33 30
Maria Engström, CFO, Sedana Medical AB
+46 70 674 33 30
Sedana Medical is listed on Nasdaq First North in Stockholm
and Erik Penser Bank (+46 8 463 83 00) is certified adviser to Sedana Medical.
Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients. A major clinical registration study is currently ongoing to obtain market approval in Europe for inhalation sedation in intensive care units with the pharmaceutical IsoConDa® (isoflurane). Sedana Medical has direct sales in the Nordic countries, Germany, France and Spain as well as external distributors in the rest of Europe, Middle East, Canada, Australia and South Korea. The company headquarters are based in Stockholm, Sweden with R&D operations in Ireland.